TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

GENFIT Announces 2026 Financial Calendar

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Genfit
GENFIT Announces 2026 Financial Calendar

GENFIT, a biopharmaceutical company focused on rare liver diseases, announced its provisional 2026 financial calendar with key dates for earnings releases, annual shareholder meeting on June 15, and publication of financial statements. The company continues development of its lead asset G1090N for ACLF and GNS561 for cholangiocarcinoma, with Iqirvo® (elafibranor) already approved and marketed for Primary Biliary Cholangitis.

Insights
GOOGL   positive

Berkshire's investment signals confidence, stock is considered cheap with strong earnings potential, and has grown 53% year-to-date


IPSEY   positive

Ipsen holds an 8% stake in GENFIT and commercializes Iqirvo® (elafibranor) in major markets including the U.S. and Europe. The drug's successful FDA/EMA approvals and market expansion represent revenue opportunities and validate Ipsen's investment in GENFIT's pipeline.